[Glucose tolerance, insulin and lipids after one week's administration of fenfluramine to overweight patients (author's transl)].
The effect of oral administration of the amphetamine derivative, fenfluramine for one week was investigated in comparison to a placebo for the same period in 28 overweight patients, 57% of whom showed a reduced glucose tolerance. In addition to glucose and insulin, the lipid fractions were also measured. In the series with pathological glucose tolerance in which the body weight remained unchanged, fenfluramine produced a lowering of the basal levels of blood sugar and insulin. After oral loading with glucose the total rise in glucose and the rise in insulin in the late phase were diminished. Free fatty acids, free glycerol, triglycerides and cholesterol were not affected.
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005277:Fenfluramine / Q000494:pharmacology*; D005951:Glucose Tolerance Test; D005990:Glycerol / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood*; D008055:Lipids / Q000097:blood*; D009765:Obesity / Q000097:blood*; D010919:Placebos; D011236:Prediabetic State / Q000097:blood; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D008055:Lipids; D010919:Placebos; D014280:Triglycerides; D005277:Fenfluramine; D002784:Cholesterol; D005990:Glycerol
Glukosetoleranz, Insulin und Lipide nach einwöchiger Fenfluramingabe bei Ubergewichtigen